Feasibility Study of Non-Expanded Autologous Adipose Tissue Derived Stromal Vascular Fraction Cells in Disease Modifying Anti-Rheumatic Drugs (DMARD) Resistant Rheumatoid Arthritis

Trial Profile

Feasibility Study of Non-Expanded Autologous Adipose Tissue Derived Stromal Vascular Fraction Cells in Disease Modifying Anti-Rheumatic Drugs (DMARD) Resistant Rheumatoid Arthritis

Withdrawn prior to enrolment
Phase of Trial: Phase I/II

Latest Information Update: 04 May 2017

At a glance

  • Drugs Stromal vascular fraction (Primary)
  • Indications Rheumatoid arthritis
  • Focus Adverse reactions
  • Sponsors Translational Biosciences
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 16 Sep 2015 Status changed from active, no longer recruiting to withdrawn prior to enrolment as reported by ClinicalTrials.gov.
    • 21 Jan 2015 Status changed from recruiting to active, no longer recruiting according to the ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top